Rankings
▼
Calendar
FOLD Q3 2023 Earnings — Amicus Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
FOLD
Amicus Therapeutics, Inc.
$5B
Q3 2023 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$104M
+26.7% YoY
Gross Profit
$94M
90.4% margin
Operating Income
-$17M
-16.4% margin
Net Income
-$22M
-20.8% margin
EPS (Diluted)
$-0.07
QoQ Revenue Growth
+9.5%
Cash Flow
Operating Cash Flow
-$38M
Free Cash Flow
-$40M
Stock-Based Comp.
$17M
Balance Sheet
Total Assets
$764M
Total Liabilities
$631M
Stockholders' Equity
$133M
Cash & Equivalents
$263M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$104M
$82M
+26.7%
Gross Profit
$94M
$68M
+37.1%
Operating Income
-$17M
-$34M
+49.7%
Net Income
-$22M
-$33M
+35.2%
Geographic Segments
Non-US
$66M
63%
UNITED STATES
$38M
37%
← FY 2023
All Quarters
Q4 2023 →